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IN TRO DUC TION
Antineutrophil cy to plas mic an ti bod ies (ANCA)
are a het er o ge neous group of cir cu lat ing an ti bod ies 
di rected to ward the cy to plas mic con stit u ents of
neutrophil gran ules and monocytes. ANCA were
first de scribed in 1982 by Davies et al. in a few pa -
tients with seg men tal necrotizing glomerulone -
phritis (1,2). The im por tance of this ob ser va tion had 
not been rec og nized un til 1985, when a dis tinct
gran u lar cy to plas mic flu o res cence pat tern, first
called ACPA (anticytoplasmic an ti bod ies) and later
termed C-ANCA (cy to plas mic), was shown to be
as so ci ated with Wegener′s granulomatosis (WG)
(3). Later, a sec ond ANCA flu o res cence pat tern
(later called perinuclear, P-ANCA) was de scribed in 
pa tients with mi cro scopic polyangiitis (MPA) (4) and 
in pa tients with the id io pathic form of pauci-im mune
necrotizing cres cen tic glomerulonephritis (iNCGN)
(5). These data have now been con firmed by many
groups and sup port the view that ANCA-as so ci ated
vasculitis and glomerulonephritis are in deed a dis -
tinct dis ease cat e gory (6-11). Sub se quently, a third, 
less clearcut ANCA sub type (later termed ‘atyp i cal’
or very perinuclear, a/P-ANCA) was de scribed in a
wide range of con nec tive tis sue dis eases (CTD),
inflammatory bowel (IBD) and autoimmune liver
diseases, and infectious diseases (8-13).
To day the var i ous ANCA serve as use ful
seromarkers. They can be used as clin i cal tools to
aid in the di ag no sis of WG and to dis tin guish new
en ti ties within the large spec tra of vasculitis/glome -
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SUM MARY Antineutrophil cy to plas mic an ti bod ies (ANCA) are a het er o ge -
neous group of cir cu lat ing an ti bod ies di rected to ward the cy to plas mic con stit u -
ents of neu tro phils and monocytes. ANCA have been de scribed in var i ous dis -
eases in clud ing id io pathic sys temic vasculitides, con nec tive tis sue dis eases,
in flam ma tory bowel dis eases, au to im mune liver dis eases, in fec tious dis eases, 
and some drugs. ANCA rec og nize dif fer ent tar get an ti gens such as proteinase
3 (PR3-ANCA), myeloperoxidase (MPO-ANCA), cathepsin G, lactoferrin, bac -
te ri cidal/per me abil ity-in creas ing pro tein (BPI), and some oth ers. How ever,
only PR3-ANCA and MPO-ANCA are closely as so ci ated with sys temic vascu li -
tides, in par tic u lar Wegener′s granulomatosis, mi cro scopic polyangiitis and its
re nal lim ited man i fes ta tion, and Churg-Strauss syn drome. Both in vi tro and in
vivo ex per i men tal data strongly sup port a patho genic role for ANCA in vasc -
ulitis and glomerulonephritis.
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ru lo nephritis and chronic in flam ma tory bowel and
liver dis eases. Re cent stud ies sup port the hy poth e -
sis that ANCA and their tar get an ti gens may be im -
pli cated in the pathogenesis of these dis eases, at
least in vasculitis (7-11,14-20).
In this re view we will eval u ate back ground in for -
ma tion about the evo lu tion of ANCA meth od ol ogy,
the di ag nos tic ap pli ca tion of ANCA test ing, and the
cur rent un der stand ing of the patho genic role of dif -
fer ent sub types of ANCA. We also dis cuss ANCA in
the con text of cutaneous vasculitis.
ANCA TEST METH OD OL OGY AND
THEIR TAR GET AN TI GENS
Cur rently, three ba sic as say prin ci ples are ap -
plied for the de tec tion of ANCA. The orig i nal me -
thod of ANCA de tec tion is in di rect immunofluores -
cence (IIF) (21). While it re mains the most widely
used method, it does not iden tify the spe cific an ti -
gen re spon si ble for the ANCA immunofluorescen -
ce. En zyme-linked immunosorbent as say (ELISA)
is used for tar get-spe cific ANCA de ter mi na tion (22). 
There are two pop u lar types of such solid-phase as -
says. The tar get an ti gen can be coated di rectly onto 
the plas tic re ac tion well (stan dard ELISA), or it can
be linked to the re ac tion well via tar get an ti gen-spe -
cific mouse monoclonal or rab bit polyclonal an ti -
bod ies (cap ture ELISA or sand wich ELISA) (23).
Other de tec tion meth ods such as radioimmunoas -
say (RIA), immunoblotting (IB) or immunoprecipita -
ti on tech niques are not widely used for routine
ANCA testing (24).
ANCA are rou tinely de tected by IIF on eth a -
nol-fixed neu tro phils (21,25,26). Re cent con sen sus 
state ments on test ing and re port ing of ANCA rec og -
nize four dif fer ent flu o res cence pat terns: a coarse
gran u lar cy to plas mic flu o res cence with ac cen tu a -
tion be tween the nu clear lobes – clas sic cy to plas -
mic or C-ANCA (Fig. 1A, e, f); a typ i cally perinuc lear 
flu o res cence with some nu clear ex ten sion (Fig. 1B,
e) and gran u lar cy to plas mic flu o res cence on for ma -
lin-fixed neu tro phils (Fig. 1B, f) – perinuclear or
P-ANCA; pro nounced nu clear rim flu o res cence
with min i mal nu clear ex ten sion, cen ter of nu cleus
un stained (Fig. 1C, e) and non-re ac tiv ity with for -
ma lin-fixed neu tro phils (Fig ure 1C; f) – very peri -
nuclear or ‘atyp i cal’ a/P-ANCA; and atyp i cal ANCA
which in clude all other IIF re ac tiv ity, most com -
monly a com bi na tion of cy to plas mic and perinucle -
ar fluorescence (not shown). 
The char ac ter is tic C-ANCA pat tern has been
rec og nized as a char ac ter is tic stain ing pat tern pro -
duced by the sera of most pa tients with WG, but
also of some 50% of pa tients with MPA and a mi nor -
ity of pa tients with other necrotizing vasculitis or id -
io pathic NCGN (27). Dif fer en ti at ing the clas sic
gran u lar cy to plas mic flu o res cence pat tern with in -
ter lob u lar ac cen tu a tion (C-ANCA) from dif fuse flat
cy to plas mic flu o res cence pat tern with out in ter lob u -
lar ac cen tu a tion (C-ANCA-atypical) pattern may at
times be difficult.
P-ANCA were orig i nally de scribed in pa tients
with id io pathic and/or vasculitis as so ci ated NCGN
(5). Fur ther stud ies showed that the P-ANCA pat -
tern could also be pro duced by the sera from pa -
tients with vasculitis with out re nal in volve ment and
pa tients with IBD, au to im mune liver dis ease, in fec -
tious dis eases such as HIV in fec tion, and very
rarely con nec tive tis sue dis ease (CTD) such as
sys temic lupus erythematosus (SLE) and rheu ma -
toid ar thri tis (RA) (11,12). The perinuclear pat tern
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Fig ure 1. Char ac ter is tic flu o res cence pat terns of anti -
neutrophil cy to plas mic an ti bod ies (ANCA) on eth a nol (e)
and paraformaldehyde (f) fixed hu man neutrophil cytospin 
prep a ra tions. (A) a coarse finely gran u lar flu o res cence
pres ent through out the cy to plasm and with ac cen tu a tion
be tween nu clear lobes (e and f)-cy to plas mic-C-ANCA;
(B) a typ i cally perinuclear flu o res cence with some nu clear 
ex ten sion (e) and a gran u lar cy to plas mic flu o res cence on
for ma lin fixed neu tro phils (f)-perinuclear-P-ANCA ; (C) a
prononuced nu clear rim flu o res cence, cen ter of nu cleus
un stained, with out the nu clear ex ten sion (e) and neg a tive
flu o res cence on for ma lin fixed neu tro phils (f) -"atyp i cal"
perinuclear -a/P-ANCA or very perinuclear P-ANCA.  
can not al ways be dis tin guished from the nu clear
stain ing pat tern. Thus, dis crim i na tion be tween anti -
nuclear an ti bod ies (ANA) and P-ANCA is not pos si -
ble in most sera that are ANA pos i tive when iso lated 
eth a nol-fixed neu tro phils are used as a sub strate.
In fact, an ti bod ies re act ing with nu clei of granu lo -
cytes only, and not with those of other sub strates,
have been de tected in pa tients with RA long be fore
ANCA had been de scribed, and were named gra -
nu lo cyte-spe cific antinuclear an ti bod ies (GS-ANA). 
Re cent stud ies, how ever, have shown that the
P-ANCA flu o res cence pat tern rep re sents an ar ti fact 
of eth a nol fix a tion which al lows for re ar range ment
of pos i tively charged gran ule con stit u ents around
and on the neg a tively charged nu clear mem brane
(28). The use of crosslinking fix a tives, such as pa -
rafo rmaldehyde, dur ing the prep a ra tion of neutro -
phil sub strates pre vents the perinuclear re ar range -
ment of charged an ti gens and thereby al lows for
dis tinc tion of true P-ANCA from ANA with or with out
granulocyte spec i fic ity. On for ma lin-fixed neu tro -
phils, true P-ANCA will dis play dif fuse gran u lar cy -
to plas mic stain ing, whereas an ANA-con tain ing se -
rum sam ple will again dis play nu clear stain ing. The
si mul ta neous test ing for ANA using standard sub -
strates, such as HEp-2 cells, is not sufficient for this
dis tinc tion because P-ANCA and ANA can occur
simultaneously.
‘Atyp i cal’ P-ANCA with dif fer ent fre quency were
found in pa tients with IBD, au to im mune liver dis -
eases and in fec tious dis eases such as HIV in fec -
tion (11,12). Dis tinc tion be tween these two P-ANCA 
sim i lar flu o res cence pat terns is pos si ble on for ma -
lin-fixed neu tro phils where the ‘atyp i cal’ P-ANCA
pat tern dis plays non-re ac tiv ity, whereas true P-
 ANCA dis play dif fuse gran u lar cytoplasmic staining
(Fig. 1).
IIF should be per formed on se rum sam ples from
all ‘new’ pa tients, since about 10% of ANCA-pos i -
tive se rum sam ples in pa tients with WG or MPA can
be dem on strated only by IIF.
To cir cum vent the prob lems as so ci ated with IIF,
i.e. the lack of tar get an ti gen spec i fic ity and op er a -
tor de pend ence, tar get an ti gen-spe cific solid-phase 
immunoassays have been used. ELISA and IB
tech niques en able iden ti fi ca tion of many tar get an ti -
gens that are as so ci ated with autoantibodies caus -
ing dif fer ent immunofluorescence pat terns (Ta ble
1). The tar get an ti gen rec og nized by most C-ANCA
pos i tive sera has been iden ti fied as proteinase 3
(PR3), a neu tral serine pro te ase pres ent in the
azurophilic gran ules of neu tro phils. Proteinase 3
has been cloned and shown to be a 29 kD glyco -
protein of 228 aminoacids (29-33). Hu man an ti bod -
ies to PR3 ap pear to rec og nize conformational de -
ter mi nants on the mol e cule (34). Very rarely, sera
with PR3-ANCA re ac tiv ity can also cause P-ANCA
flu o res cence pat tern (35). Myeloperoxidase (MPO)
rep re sents the P-ANCA tar get an ti gen with the
great est clin i cal util ity be cause of the fre quent as so -
ci a tion of MPO-ANCA with MPA and iNCGN (36).
All se rum sam ples should be as sayed in PR3-
 ANCA and MPO-ANCA ELISAs, since about 5% of
se rum sam ples are pos i tive only by ELISA. How -
ever, many sera that pro duce P-ANCA or a/P-ANCA 
stain ing pat tern on eth a nol-fixed neu tro phils do not
con tain autoantibodies to MPO or PR3 as tested by
an ti gen-spe cific as says. It has now been rec og -
nized that a num ber of these sera con tain an ti bod -
ies to other gran u lar con stit u ents of neu tro phils. In
par tic u lar, autoantibodies have been dem on strated
to hu man leu ko cyte elastase (HLE) (37,38), cathe -
psin G (CG) (39-42), lactoferrin  (LF) (43-46), lyso -
zyme (47), azurocidin (48), α-enolase (49-51), actin 
(52-54), tropomyosin (53, 54), high mo til ity groups
of nonhistone chro mo somal pro teins 1 and 2
(HMG1 and HMG2) (55-57), bac te ri ci dal/ per me a -
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Ta ble 1. Tar get an ti gens for antineutrophil cy to -
plas mic an ti bod ies (ANCA)
ANCA target antigen Immunofluorescence pattern
PR3 C-ANCA, very rarely P-ANCA   














bi l ity- in creas ing protein (BPI) (58-61), lamin B1 (13, 
47) and histone H1 (13,62). 
DI AG NOS TIC UTIL ITY OF ANCA
TEST ING
Since the first de scrip tion of ANCA, the dif fer ent
ANCA flu o res cence pat terns have been de scribed
in var i ous dis eases. In ad di tion to sys temic vascu -
litides, this list now in cludes var i ous CTDs, IBD, au -
to im mune liver dis eases, in fec tions, ma lig nan cies,
myelodysplastic pro cesses and many oth ers, even
di a be tes mellitus. The in ter pre ta tion of many re -
ports is com pro mised by lim ited in for ma tion about
the meth ods uti lized for ANCA de tec tion. Re ports
that in clude data on dif fer ent flu o res cence pat terns
and spe cific tar get an ti gens al low for more mean -
ing ful analysis of clinical as so ci a ti ons and utility.
ANCA in pri mary sys temic vasculitides 
The most clear-cut as so ci a tion of a dis ease with
ANCA di rected against a spe cific tar get an ti gen re -
mains the as so ci a tion be tween WG and PR3-
 ANCA (Ta ble 2). Be tween 80% to 95% of all ANCA
found in WG are C-ANCA (8,12,63-65). The use of
more sen si tive PR3-ANCA spe cific meth ods (cap -
ture ELISA) of de tec tion has con firmed that the
C-ANCA in WG is al most al ways as so ci ated with
anti-PR3 (23,66). It has been es ti mated that
5%-20% of ANCA in WG may be P-ANCA, which
are mostly di rected against MPO (67,68) and only
rarely against other known tar get an ti gens such as
hu man leu ko cyte elastase (69). The sen si tiv ity of
C-ANCA/PR3-ANCA for WG is re lated to the ex tent, 
se ver ity and ac tiv ity of dis ease (64). In a meta-anal -
y sis of C-ANCA in WG, the pooled sen si tiv ity was
91% for the sub set of pa tients with ac tive dis ease
com pared to 63% for those with in ac tive dis ease
(70). Some lon gi tu di nal stud ies have shown that
titers of C-ANCA/PR3-ANCA cor re late with clin i cal
dis ease ac tiv ity (71-74), al though this has been dis -
puted by other au thors (75,76). Ad di tion ally, dis -
ease re lapse can be an tic i pated and pre vented by
in ten si fy ing immunosuppression in re sponse to ris -
ing titers (76,77). Per sis tent or intermittent C-ANCA
positivity is an independent risk factor for relapse
(78-81).
Most pa tients with MPA are ANCA pos i tive, ei -
ther with spec i fic ity for MPO or for PR3 (5,11,12,64,
67). The in ter pre ta tion of data about the as so ci a tion 
of ANCA and MPA is com pli cated by the lack of con -
sen sus about the def i ni tion of MPA. Since there
con tin ues to be con tro versy about which fea tures
clearly sep a rate MPA from PAN, it re mains un clear
whether ANCA also oc cur in some pa tients with
clas sic PAN (82). How ever, most data sup port the
per cep tion that MPA, which is fre quently as so ci ated 
with GN and/or pul mo nary capillaritis, is of ten as so -
ci ated with MPO-ANCA, whereas clas sic PAN is not  
(64,83,84). The re la tion be tween titers of ANCA and 
dis ease ac tiv ity has not been studied systematically 
in MPA (70,78,80,85).
Other tar get an ti gens for ANCA, such as BPI
and azurocidin, have re cently been de tected in pa -
tients with sys temic vasculitis (48,58,60,86). These
an ti bod ies may also si mul ta neously oc cur with
PR3- or MPO-ANCA.
Most pa tients with iNCGN are pos i tive for
anti-MPO, the re main ing gen er ally be ing pos i tive
for anti-PR3 (5,11,12,68,87). Many of these pa -
tients have con sti tu tional symp toms to gether with
signs of sys temic in volve ment so that the dis tinc tion 
be tween WG, MPA and iNCGN is far from absolute.
ANCA have been de tected with vari able fre -
quency in pa tients with CSS (88-90). Both MPO
and PR3 have been de scribed as tar get an ti gens.
Al though Ig-A-ANCA have oc ca sion ally been
noted in Henoch-Schönlein purpura (91-93), most
stud ies have not shown this to be a sig nif i cant as so -
ci a tion with re gard to ei ther fre quency or clin i cal
fea ture of illness (94).
Pa tients with Kawasaki dis ease may have
ANCA and antiendothelial cell an ti bod ies (AECA)
but these an ti bod ies oc cur in the mi nor ity of pa -
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Ta ble 2. Dis ease as so ci a tions of C-ANCA (PR3-
 ANCA) and P-ANCA (MPO-ANCA) in sys temic vas -
cu litis
Patients Sensitivity of
with C-ANCA PR3-ANCA P-ANCA MPO-ANCA
WG 80-90 85  5-20 24
MPA 35-45 26 40-50 58
iNCGN 30-40 50 46-65 58
CSS 14-33 33 33-42 50
PAN  3-10  0  5-30 38
tients and do not oc cur more of ten than in other pe -
di at ric fe brile illneses (95,96).
Other forms of vasculitis, par tic u larly gi ant cell
arteritis, Takayasu arteritis and Behcet′s dis ease,
are not ANCA-as so ci ated (97,98).       
ANCA in con nec tive tis sue dis eases
(CTD)
ANCA have been de scribed in pa tients with a
va ri ety of CTD, in clud ing RA (99-104), SLE (105-
 107), PM/DM (108), ju ve nile chronic ar thri tis (109),
re ac tive ar thri tis (110,111), re laps ing chondritis
(112,113) and anti-phospholipid syn drome (108).
ANCA in scleroderma is un com mon and is of doubt -
ful clin i cal sig nif i cance (114,115). The flu o res cence
pat terns in CTD are mostly P-ANCA. To a lesser ex -
tent, atyp i cal flu o res cence pat terns may be found,
and true C-ANCA pat terns are rare (108,116). A
mul ti tude of tar get an ti gens, in clud ing LF, HLE,  LZ,
CG, MPO, HMG1 and HMG2, have been de scribed
in these dis eases (Ta ble 3). How ever, a sig nif i cant
pro por tion of tar get an ti gens for ANCA en coun tered 
in this set ting re main to be iden ti fied. PR3-ANCA
occur extremely rarely in these patients (116).
While pa tients with CTD have an in creased fre -
quency of vasculitis, data to sug gest that ANCA
positivity en hances the risk of vasculitis are con tra -
dic tory (108,116). Non-vasculitis as pects of rheu -
matic dis ease ac tiv ity, se ver ity and chronicity also
fail to con sis tently cor re late with ANCA sta tus
(100,102,103,108,116). Con se quently, there is lit tle 
clin i cal util ity for ANCA test ing in pa tients with CTD
in whom one of the ANCA-as so ci ated sys temic
vasculitides is not suspected.
ANCA in in flam ma tory bowel dis ease
(IBD) and au to im mune liver dis eases
Shortly af ter the dis cov ery of ANCA in WG and
MPA, ANCA were dis cov ered in IBD and au to im -
mune liver dis eases (13,117-125). On IIF these
ANCA pro duce perinuclear and less of ten atyp i cal
cy to plas mic flu o res cence pat terns. MPO is not a
prom i nent tar get an ti gen for these P-ANCA (Ta ble
4). A mul ti tude of other tar get an ti gens, par tic u larly
LF, CG, actin, BPI, catalase and HMG1/2, have
been iden ti fied as tar get an ti gens in IBD (13,39-
 41,45,126-128). Data from most se ries sug gest that 
the prev a lence of P-ANCA is higher in ul cer ative co -
li tis (40%-80%) than in Crohn′s dis ease (10%-
 40%). Some stud ies have sug gested a higher as so -
ci a tion of ANCA in pa tients with Crohn′s dis ease
and co lonic in volve ment (129,130), treat ment-re -
sis tant left-sided ul cer ative co li tis (131) or chronic
pouchitis (132,133). The over lap of ANCA find ings
be tween the var i ous clin i cal groups of IBD pa tients
is sig nif i cant. There fore, ANCA test ing does not fa -
cil i tate the dif fer en tial di ag no sis of pa tients with
IBD. Nei ther is the cor re la tion of titers with dis ease
activity sufficiently reliable to be useful for mon i tor -
ing IBD activity (13,123,124,129).
ANCA are also fre quently found in pa tients with
pri mary sclerosing cholangitis (PSC) and au to im -
mune hep a ti tis type 1 (50%-90%). ANCA are gen er -
ally not as so ci ated with pri mary biliary cir rho sis
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Ta ble 3. Tar get an ti gens of ANCA in con nec tive tis -
sue dis eases (CTD)
Patients Target antigens in ELISA (%)
with PR3 MPO LF CG HMG1/2
SLE 0  1 11 37 37/18
RA 0  1 35 33 40/25
SS 0  0  0 22 44/11
SSc 0 18  5  5 36/18
PM/DM 0  0 27  9 18/18
SLE=systemic lupus erythematosus; RA=rheumatoid arthritis;
SS=Sjögren’s syndrome; SSc=systemic sclerosis;
PM/DM=polymyositis/dermatomyositis; PR3=proteinase 3;
MPO=myeloperoxidase; LF=lactoferrin; CG=cathepsin G;
HMG1/2=high mobility group (HMG) nonhistone chromosomal
proteins 1 and 2
Ta ble 4. Tar get an ti gens of ANCA in pa tients with
in flam ma tory bowel and au to im mune liver dis e -
ases
Patients Target antigen in ELISA (%)
with MPO LF CG Actin BPI Catalase HMG1/2
UC 2-29 5-50 0-1  NT 43 38 32
CD  0-6 1-21 0-2  NT 26 26 26
PBC  NT  NT NT  NT 25 NT NT
PSC 0-33 0/50 NT  NT 35 NT NT
AIH type 1  NT 8 0 47-52 29 NT NT
UC=ulcerative colitis; CD=Crohn’s disease; PBC=primary biliary
cirrhosis; PSC=primary sclerosing cholangitis; AIH=autoimmune
hepatitis; BPI=bactericidal/permeability increasing protein;
HMG1/2=high mobility group (HMG) nonhistone chromosomal
proteins 1 and 2; NT=not tested
(13,121,122,134-136). ANCA re ac tiv ity in au to im -
mune hep a ti tis type 1 most of ten ap pears to be di -
rected to actin (13,54,136).
ANCA in in fec tious dis eases
ANCA, mainly with ‘atyp i cal’ cy to plas mic or P-
 ANCA immunofluorescence pat terns, have been
de scribed in hu man im mu no de fi ciency vi rus (HIV)
in fec tion (137,138), cys tic fi bro sis with bac te rial air -
way in fec tions (139,140), chromomycosis (141),
acute ma laria (42,142), in va sive amebiasis (143),
and in pa tients with some other in fec tions (144,
145). These ANCA are not caused by an ti bod ies
against PR3 and MPO. A re cent re port has de -
scribed the oc cur rence of BPI-IgG-ANCA and BPI-
 IgA-ANCA in the ma jor ity of pa tients with cys tic fi -
bro sis (146). Anti-BPI titers were di rectly re lated to
the se ver ity of air way de struc tion. Cathepsin G has
been iden ti fied as the most sig nif i cant tar get an ti -
gen for ANCA, caus ing an atyp i cal cy to plas mic flu o -
res cence pat tern in pa tients with acute ma laria
(42,142). In va sive amebiasis is the only in fec tion
that has been re ported to be as so ci ated with PR3-
 ANCA (143). The pres ence of autoantibodies caus -
ing cy to plas mic flu o res cence on eth a nol-fixed neu -
tro phils from pa tients with in fec tion shows the im -
por tance of ex clud ing in fec tious pro cesses be fore
ini ti at ing immunosuppressive ther apy. These ob -
ser va tions may sug gest that ANCA, which oc cur
tran siently in the set ting of in fec tion, and the per sis -
tent ANCA in pa tients with vasculitis may be the re -
sults of mo lec u lar mim icry in sus cep ti ble hosts
(147). Sub se quent di ver si fi ca tion of T- and B-cell
re sponses (‘epitope spread ing’) may lead to re -
sponse against dif fer ent epitopes on the same
target molecule (intramolecular spreading) or may
extend to other molecules (intermolecular spread -
ing) (148,149).
ANCA as so ci ated with drugs
In creas ing num bers of case re ports and re ports
of small se ries have iden ti fied as so ci ated dis eases
that are pre sumed to be in duced by cer tain drugs
with ANCA re ac tiv ity. The fol low ing drugs have
been con nected to au to im mune clin i cal se quels
and ANCA: hydralazine-in duced lupus with anti-
 MPO and elastase an ti bod ies, hydralazine-as so ci -
ated vasculitis with anti-MPO and anti-LF an ti bod -
ies and minocycline-in duced ar thri tis, fe ver, and li -
ve do reticularis with anti-MPO an ti bod ies (150-
 156). Vasculitis oc cur ring af ter propylthiouracil ther -
apy has been as so ci ated with ANCA specificities to
sev eral dif fer ent tar get an ti gens, including PR3,
MPO and elastase (152,153,157-160).
Di ag no sis of cu ta ne ous man i fes ta tions
of We ge ner′s granulomatosis (WG)
and mi cro scopic po ly angiitis (MPA)
WG and MPA are the pro to type sys temic dis -
eases as so ci ated with ANCA. Cu ta ne ous le sions
may oc cur in up to one-half of pa tients with WG (Ta -
ble 5) (161-163). In gen eral, cu ta ne ous le sions are
more likely in pa tients who have mul ti ple or gan sys -
tem in volve ment. Cu ta ne ous le sions may also be
the first man i fes ta tion of WG and may not be
vasculitic. Pa tients may de velop cu ta ne ous le sions
be fore the on set of up per air way or pul mo nary or re -
nal symp toms, mak ing the di ag no sis of WG very dif -
fi cult for der ma tol o gist. Some pa tients may de velop
more than one type of cu ta ne ous le sions, which
may change over time or with treat ment. In or der to
best uti lize lab o ra tory test ing for ANCA, it is es sen -
tial to rec og nize the cu ta ne ous pat terns of WG and
MPA, and, more im por tant, to rec og nize those dis -
or ders that can sim u late cu ta ne ous le sions seen in
WG (Ta ble 6). Spe cific le sions are de fined as be ing
di rectly re lated to WG and not as the re sults of in -
fec tion, drug sen si tiv ity or other de fin able causes
other than WG. The most com mon spe cific man i -
fes ta tion of cu ta ne ous WG are pal pa ble purpura
and ul cer ation with the histopathologic cor re la tion
of leukocytoclastic vasculitis (LCV), most of ten
with out granuloma for ma tion, and with a histo -
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Ta ble 5. Char ac ter is tic in volve ment of Wegener’s











patho logic cor re late of acute and/or granulomatous
in flam ma tion, re spec tively. Many other di ag nos tic
en ti ties with cu ta ne ous man i fes ta tions are to be
con sid ered on the dif fer en tial di ag no sis of WG (Ta -
ble 6). Di ag nos tic al go rithm for cu ta ne ous WG in -
cludes care ful clin i cal ex am i na tion and clin i cal
patho logic cor re la tion to con firm the di ag no sis (Ta -
ble 7). Test ing of ANCA may play a sig nif i cant role in 
the eval u a tion of pa tients sus pected to have sys -
temic vasculitis or an other ill ness with pre sen ta tion
sim i lar to WG. Only a pos i tive C-ANCA (IIF) with a
pos i tive PR3-ANCA (ELISA) re sult, and a pos i tive
P-ANCA (IIF) with a pos i tive MPO-ANCA (ELISA)
re sult are sen si tive and spe cific for WG and MPA.
Re peat ANCA test ing is war ranted to fol low the
course of the dis ease in pa tients who have proven
WG or MPA as ANCA lev els cor re late loosely with
dis ease ac tiv ity and re lapses in the ab sence of
ANCA are rare. A pa tient with LCV and other cu ta -
ne ous find ings sug ges tive of WG with a pos i tive
C-ANCA/PR3-ANCA or P-ANCA/MPO-ANCA test
result should be followed carefully for subsequent
development of systemic disease manifestations
even if there is no sign of internal organ involvement 
at the time of initial presentation.
DE VEL OP MENT OF ANCA AND THEIR
ROLE IN THE PATHOGENESIS OF
VASCULITIS
In ter ac tion of ANCA with their tar get
an ti gens
PR3-ANCA are able to in hibit en zy matic ac tiv ity
of na tive and re com bi nant PR3 by bind ing near the
cat a lytic do main (164). Anti-PR3 an ti bod ies pre vent 
the in ac ti va tion of PR3 by its nat u ral in hib i tor alfa-1
antitrypsin (α1-AT) (165). The in hib i tory ac tiv ity dif -
fers be tween sera and is not di rectly re lated to the
amount of spe cific an ti body. In a lon gi tu di nal study it 
has been shown that dis ease ac tiv ity in pa tients
with WG cor re lates with the amount of in hib i tory ac -
tiv ity of the se rum rather than with the ti ter of
PR3-ANCA (166). Like wise, MPO-ANCA may in ter -
fere with bind ing of MPO to its nat u ral in hib i tor ceru -
loplasmin (167). This suggets that es cape of the en -
zyme from its inactivation may contribute to the in -
flam ma tory process.
The phenotypic ex pres sion of α1-AT is highly
poly mor phic: se verely, me dium and non-de fi cient
pro teinase in hib i tor phe no types can be dis tin -
guished (168,169). The prev a lence of ANCA of di -
verse spec i fic ity was re mark able among a pop u la -
tion with the se verely de fi cient phe no type (170).
These data sug gest that de fi cient α1-AT ac tiv ity is
involved in the induction of ANCA.
In ter ac tion of ANCA with en do the lial
cells
As men tioned above, the an ti gens rec og nized
by MPO-ANCA and PR3-ANCA are con stit u ents of
gran ules from myeloid cells and are thought to be
spe cific for cells of the monomyeloid lin eage. Re -
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Ta ble 6. Di ag nos tic en ti ties with cu ta ne ous man i -
fes ta tions to be con sid ered on dif fer en tial di ag no -
sis of cu ta ne ous Wegener’s granulomatosis
Leukocytoclastic or granulomatous vasculitis
Pyoderma gangrenosum
Neutrophilic dermatoses
Infection (bacterial, fungal, mycobacterial)
Infestation (e.g., amebiasis)
Malignancy (lymphoma, lymphomatpoid granulomatosis,
 leukemia cutis)
Cutaneous Crohn’s disease
Drug reactions (including hydralazine and minocycline)
Panniculitis (alpha-1 antitrypsin deficiency, erythema
 nodosum)





Ta ble 7. Di ag nos tic al go rithm in dif fer en tial di ag no -
sis of cu ta ne ous Wegener’s granulomatosis
Characteristic clinical findings (purpura, ulcerations,
 nodules, etc.)
Biopsy for routine microscopy and special stains for
 microorganisms
Biopsy for tissue culture*
Serologic tests including ANCA (IIF and ELISA)
Longitudinal follow up of ANCA
*Recommended in the majority of cases if histopathology or clinical
findings may also be compatible with infectious cause.
ANCA-antineutrophil cytoplasmic antibodies; IIF-indirect
immunofluorescence; ELISA-target antigen-specific solid-phase
assay 
cent stud ies have dem on strated, how ever, that
PR3 can be ex pressed in other cell types as well, in
par tic u lar in re nal car ci noma cells (171) and hu man
en do the lial cells (172). These cells, primed by
cytokines (TNF-α, IL-1, IFN-γ), ex press PR3 in their 
cy to plasm and cell sur face mak ing PR3 avail able
for in ter ac tion with ANCA. Oth ers have not been
able to show en do the lial PR3 ex pres sion (173).
MPO and PR3 are cationic pro teins and as such
may bind to an ionic struc tures such as the glo mer u -
lar base ment mem brane (GBM) and the sur face of
en do the lial cells. It has, in deed, been shown that
ANCA can bind to cul tured hu man en do the lial cells
in cu bated with MPO (174). Un der these con di tions,
anti-MPO can in duce com ple ment-de pend ent en -
do the lial cell lysis. In vi tro in cu ba tion of en do the lial
cells with PR3 in duces pro duc tion of IL-8, en do the -
lial cell apoptosis, and de tach ment and lysis of the
en do the lium (175-177). Al though these in vi tro
stud ies have dem on strated that ANCA can in ter act,
di rectly or in di rectly, with en do the lial cells, di rect
immunofluorescence stud ies from lesional tis sue
have failed to show sig nif i cant de po si tion of IgG
along the en do the lium or the glo mer u lar cap il lary
wall. Thus, the in vivo rel e vance of those in vitro
studies has yet to be established.
ANCA-me di ated neutrophil and
monocyte ac ti va tion 
In vi tro ac ti va tion of neu tro phils by PR3- and
MPO-ANCA re quires prior prim ing of cells by low
doses of proinflammatory cytokines, such as
TNF-α, IL-1β or LPS. Prim ing is as so ci ated with
translocation of ANCA tar get an ti gens on the sur -
face of neu tro phils, which makes them ac ces si ble
for in ter ac tion with an ti bod ies (178-180). ANCA
(anti-PR3 or anti-MPO), bound to ap pro pri ately dis -
played tar get an ti gens, have been shown to en -
hance neutrophil ox i da tive burst and degranulation
(178,179,181,182). Re leased neutrolytic en zymes
may pro duce tis sue in jury by means that in clude in -
duc tion of en do the lial cell apoptosis, de tach ment
and cytolysis (176,177,183,184). In ad di tion, they
se crete in flam ma tory me di a tors such as TNF-α,
IL-1, IL-8 and leukotriene B4 (185,186). Upon ac ti -
va tion by ANCA, PMN ex press in creased lev els of
ad he sion mol e cules, in clud ing β2-integrins, that fa -
cil i tate bind ing to and transmigration through the
endothelial monolayer (187,188). 
The pre cise mech a nism un der ly ing ANCA-in -
duced neutrophil ac ti va tion is un clear. It ap pears
that neutrophil ac ti va tion in volves both spe cific
bind ing of the an ti bod ies via F(ab′)2-frag ments to
sur face ex pressed PR3 or MPO and in ter ac tion of
their Fc-frag ments with FcγR on neu tro phils, par tic -
u larly with FcγRIIa-re cep tor (189,190). Very re -
cently, it has been shown that li ga tion of FcγRIIa
and FcγRIIIb is nec es sary for ANCA-in duced
neutro phil ac ti va tion, but that sig nal ing cas cades by 
ANCA were dif fer ent from the sig nal path ways used 
by FcγR engagement only (191).
The ef fect of ANCA on monocytes has been
stud ied to a lesser ex tent. ANCA have been shown
to ac ti vate monocytes to the pro duc tion of re ac tive
ox y gen spe cies (192), IL-8, a po tent at trac tant for
PMN (193), and monocyte chemoattractant pro -
tein-1(MCP-1), even with out prior prim ing (194). In -
creased pro duc tion of MCP-1 at the site of in flam -
ma tion could play an im por tant role in the for ma tion
of granulomas by am pli fi ca tion of lo cal monocyte
re cruit ment. Monocytes from the pe riph eral blood
of pa tients with WG showed the pres ence of MPO
and PR3 on their cell sur face dur ing ac tive dis ease,
and monocytes do ex press the FcγRIIa receptor
and CD18 (195).
T-cell re ac tiv ity to ANCA-as so ci ated
an ti gens
The pres ence of cel lu lar in fil trates in in flam ma -
tory le sions, frenquently also in the form of granu -
lomas, in pa tients with WG and some other vascu -
litis, such as polyarteritis nodosa, Kawasaki and
Takayasu′s dis ease, sug gests an im por tant role of
cell-me di ated im mu nity in the pathogenesis of
these dis eases (196-200). Immunopathologic stud -
ies have shown that the in flam ma tory in fil trate is
com posed mainly of ac ti vated T-lym pho cytes, the
ma jor ity of which are CD4+ and macrophages
(196,197,199,201-203). In agree ment with these
data, the lev els of sol u ble IL-2 re cep tor are el e vated 
in WG pa tients and in crease prior to ma jor re -
lapses, pro vid ing in di rect ev i dence for a role of ac ti -
vated T-cells in sys temic vasculitis (204,205).
T-lym pho cytes iso lated from WG pa tients pro lif er -
ate in re sponse to a crude neutrophil ex tract con -
tain ing PR3 and MPO (206,207). WG pa tients re -
ACTA DERMATOVENEROLOGICA CROATICA 301
Malenica et al: Acta Dermatovenerol Croat
ANCA: Di ag nos tic and Patho genic Po ten tial 2004;12(4):294-313
sponded more fre quently and strongly to PR3 than
con trols (208,209). How ever, not all WG pa tients
re sponded to PR3, and T-cell pro lif er a tion was also
found in healthy con trols (209). In this study, strong
IL-10 pro duc tion elic ited by PR3 in vi tro may have
an im por tant func tion in vivo. Re cently, it has been
shown that B-lym pho cyte ac ti va tion is re lated to ac -
tive dis ease, whereas T-lym pho cyte ac ti va tion per -
sists dur ing re mis sion of the dis ease in pa tients with 
WG, which points to an in trin si cally dis or dered im -
mu ne sys tem in this dis ease.   
The in vivo role of ANCA in
ex per i men tal mod els
Al though all of the afore men tioned mech a nisms
may be op er a tive in vivo in  id io pathic vasculitis,
con clu sive ev i dence for the patho ge nic ity of ANCA
awaits a con vinc ing an i mal model of ANCA-in -
duced vasculitis. Sev eral an i mal mod els have now
emerged that may be rel e vant in this re spect (17).
Un for tu nately, hu man anti-PR3 an ti bod ies only re -
act with neu tro phils of ba boons and not with those
of lower spe cies. Also, im mu ni za tion of rats with hu -
man PR3 does not re sult in an ti bod ies re act ing with
rat neu tro phils. In ter est ingly, a re cent study has
shown that rats in jected with syngeneic rat
apoptotic neu tro phils de velop ANCA, but the spec i -
fic ity of these ANCA could not be es tab lished and
they did not seem to be PR3 or MPO (210). Re -
cently, PR3 has been de tected and cloned in mice
(211). Un for tu nately, monoclonal and polyclonal an -
ti bod ies to hu man PR3 do not re act with cloned
mouse PR3. Antihuman PR3 was in duced in mice
by idiotypic ma nip u la tion (212,213). The mice were
im mu nized with af fin ity-pu ri fied PR3-IgG from two
WG pa tients (212). Af ter two weeks, mice de vel -
oped anti-idiotypic (mouse anti-hu man anti-PR3
an ti bod ies, ab2) and, af ter four months, anti-anti-
 idiotypic an ti bod ies re act ing with hu man PR3 (ab3). 
In ad di tion, the sera de rived from these mice also
re acted with hu man MPO and en do the lial sur face
pro teins. Histopathologically, ster ile microabsces -
ses de vel oped in the lungs af ter eight months, and
mice died at 8-15 months af ter im mu ni za tion with
anti-PR3-IgG. The ab3 an ti bod ies were tested for
their neutrophil ac ti vat ing abil ity show ing that these
an ti bod ies were ca pa ble to in duce ad he sion of hu -
man neu tro phils to fibronectin and to ini ti ate a re spi -
ra tory burst (213). These stud ies dem on strate that
dysregulation of the idiotypic net work may lead to
the de vel op ment of patho genic autoantibodies.
Whether this the ory is rel e vant for the induction of
ANCA-associated vasculitis cannot, however, be
proven until pathogenic idiotypes on bacterial or
viral antigens are identified.
Sev eral an i mal mod els for anti-MPO-as so ci ated 
vasculitis/glomerulonephritis have been de scribed.
Brown Nor way rats (the Th2-re sponder type), ex -
posed to mer cu ric cloride (HgCl2), de vel oped a
gen er al ized au to im mune dis ease, me di ated by
T-cell de pend ent polyclonal B-cell ac ti va tion (214).
The HgCl2-in duced au to im mune syn drome is char -
ac ter ized by lymphoproliferation, high IL-4 pro duc -
tion and hypergammaglobulinemia (215). In ad di -
tion, a mul ti tude of IgG autoantibodies ap peared in
these rats, in clud ing an ti bod ies to DNA, col la gen,
thy ro glob u lin and com po nents of the glo mer u lar
base ment mem brane (216,217). In ad di tion to the
above autoantibodies, HgCl2-treated rats de vel -
oped an ti bod ies to MPO (218). These rats also de -
vel oped wide spread tis sue in jury in clud ing necro -
tizing vasculitis in the submucosal ves sels of the
du o de num and ce cum (219). Sub se quent stud ies
have dem on strated an im por tant role for autore -
active CD4+ T cells which, upon trans fer into
healthy an i mals, can in duce the dis ease (220). On
the other hand, it was shown that CD4+OX22 high
T-cells were pro tec tive since de ple tion of these
cells ag gra vates the se ver ity of tis sue in jury, al -
though the autoantibody re sponse was not af fected
(221). Treat ment with cyclosporine dur ing the early
phase of the dis ease di min ished tis sue in jury and
de layed the rise in anti-MPO and anti-GBM auto -
anti bodies (222). In con trast, treat ment with cyclo -
sporine dur ing the late phase of the dis ease ex ac er -
bated tis sue in jury al though the de vel op ment of
anti-MPO and anti-GBM autoantibodies was com -
pletely suppressed. Taken together, these ob ser va -
tions suggest that HgCl2-induced vasculitis is pri -
mar ily T-cell dependent.
The MRL/lpr strain of mice spon ta ne ously de -
velop lymphoproliferation, proliferative glomerul o -
nephritis and sys temic necrotizing vasculitis of
small and me dium-sized ar ter ies and ar te ri oles,
that par tic u larly af fect the kid ney and gall blad der
(223,224). The spon ta ne ous de vel op ment of tis sue
in jury in these mice is im mu no log i cally char ac ter -
ized by ac cu mu la tion of T-cells with polyclonal
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B-cell stim u la tion re sult ing in the ap pear ance of
rheu ma toid fac tors and autoantibodies of di verse
spec i fic ity in clud ing autoantibodies against ds-
 DNA, ss-DNA, his tones, smooth mus cle and ANCA
(225). How ever, monoclonal IgG an ti bod ies de rived 
from these mice were found to be polyreactive,
recognizing MPO, LF and DNA (226).
SCG/KJ strain of mice, de rived from the F1 hy -
brid of BXSB and MRL/lpr mice, spon ta ne ously de -
velop rap idly pro gres sive glomerulonephritis and
necrotizing vasculitis (227). The sera from these
mice pro duce a perinuclear ANCA stain ing pat tern
on hu man and murine neu tro phils and re act with
murine neutrophil ex tract and hu man MPO by
ELISA (228,229). Trans fer of MPO spe cific hybrido -
mas de rived from SCG/KJ mice into the peri to neum 
of nude mice in duced proteinuria, al though histolo -
gical ly no ev i dence for glomerulonephritis or vascu -
litis was found (228).
In duc tion of a se lec tive au to im mune re sponse to 
MPO is a more di rect method of study ing the
pathophysiologic role of anti-MPO. Im mu ni za tion of 
Brown Nor way rats with hu man MPO in com plete
Freund′s adjuvant re sults in the de vel op ment of
anti-hu man MPO an ti bod ies cross-re act ing with rat
MPO and de layed-type hy per sen si tiv ity to hu man
MPO (230,231). The au to im mune re sponse alone
does not re sult in clin i cal le sions. How ever, af ter
uni lat eral per fu sion of the left kid ney with prod ucts
of ac ti vated neu tro phils con sist ing of proteolytic en -
zymes (HLE and PR3), MPO and its sub strate
H2O2, these MPO-im mu nized rats de velop necr o -
tizing cres cen tic glomerulonephritis with in ter sti tial
tubulonephritis and vasculitis. Sys temic in jec tion of
lysosomal en zymes, MPO and H2O2 in the jug u lar
vein of MPO-im mu nized rats also re sulted in small
ves sel vasculitis and gi ant cell for ma tion in the
lungs and guts but not in the kid neys (231). The lo -
cal iza tion of the in flam ma tory pro cess in the lungs
and guts sug gests that local factors, e.g., mu -
cosa-as so ci ated microbial elements, are involved.
The patho genic po ten tial of anti-MPO an ti bod -
ies in vivo has also been dem on strated in glo mer u -
lar base ment mem brane (anti-GBM) ne phri tis in
Brown Nor way rats pre vi ously im mu nized with hu -
man MPO (232). Im mu nized rats not only de vel -
oped an ti bod ies to hu man MPO but to rat MPO as
well. Fol low ing in jec tion of a subnephritogenic dose 
of rab bit anti-rat GBM an ti bod ies, se vere glomeru -
lonephritis de vel oped char ac ter ized by hematuria,
proteinuria, fibrinoid ne cro sis of glo mer u lar cap il lar -
ies, ex ten sive fi brin ac cu mu la tion of monocy t -
es/mac ro phages and cres cent for ma tion. In con trol
im mu nized rats in jected with the anti-GBM an ti bod -
ies, only mild glomerulonephritis was found with out
ev i dence for cres cent for ma tion, sug gest ing that
the autologous anti-rat MPO antibodies are re s pon -
si ble for the exacerbation of the anti-GBM disease.
These stud ies suport the hy poth e sis that the
pres ence of ANCA it self is not suf fi cient to cause tis -
sue in jury. Ad di tional fac tors in duc ing a proinflam -
matory en vi ron ment are needed, which ini tially re -
sult in prim ing of neu tro phils and monocytes and
ac ti va tion of the en do the lium. Af ter that, ANCA ac ti -
vate primed neu tro phils/monocytes and form in situ
im mune com plexes with ANCA an ti gens re leased
from ac ti vated neu tro phils, thereby ex ac er bat ing
the in flam ma tory re sponse and fi nally leading to
vas culitis and tissue destruction.
IN TE GRA TIVE VIEW OF THE
PO TEN TIAL IM MUNE MECH A NISMS
IN THE PATHOGENESIS OF
ANCA-AS SO CI ATED VASCULITIS
Sche matic pre sen ta tion of an in te gra tive view of
ANCA-me di ated vas cu lar tis sue dam age is shown
in Fig ure 2. The model is based on the four pre req -
ui sites for en do the lial cell dam age by ANCA: 1) the
pres ence of ANCA; 2) ex pres sion of tar get an ti gens 
for ANCA on primed neu tro phils and monocytes; 3)
the ne ces sity of an in ter ac tion be tween primed neu -
tro phils and en do the lium by means of β2-integrins;
and 4) ac ti va tion of endothelial cells (7,8,16-20).
In fec tion or other tis sue in jury in duces an in flam -
ma tory re sponse as so ci ated with cytokine re lease
(TNF-α, IL-1β) re sult ing in prim ing of neu tro phils
and/or monocytes. Prim ing of these cells prompts
ex pres sion of ANCA tar get an ti gens (PR3, MPO) on 
their sur face. In this man ner the autoantigen be -
comes ac ces si ble to the cir cu lat ing ANCA. Primed
neu tro phils and monocytes also ex press Fcγ-re -
cep tors on their sur face. Con se quently, ANCA can
bind to their sur face via their con stant re gion (Fc).
Si mul ta neous bind ing of cir cu lat ing an ti gen re -
leased from ac ti vated in flam ma tory cells may
cause crosslinking of Fcγ-re cep tors initating the
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Fcγ- re cep tor engagement-dependent activation
events.
The mech a nisms by which ANCA pro duc tion is
trig gered and per pet u ated re main un clear. It has
been pos tu lated that superantigens and de fect(s) in 
apoptosis or in the re moval of apoptotic cells may
lead to the de vel op ment of ANCA through by pass -
ing nor mal mech a nisms of tol er ance (233,234). It is
well known that superantigens from bac te ria and vi -
ruses ac ti vate large pop u la tions of T-cells ex press -
ing β-chain vari able gene seg ments of the T-cell re -
cep tor (TCR-Vβ). These T-cells pro duce large
amounts of proinflammatory cytokines and help the
autoreactive B-cells pro duce ANCA. It has been re -
ported that the ma jor ity of pa tients with WG are
chronic na sal car ri ers of Staph y lo coc cus aureus
and that car ri ers ex pe ri ence a re lapse nearly eight
times more fre quently than noncarriers (79). Some
stud ies in these pa tients have dem on strated skew -
ing of the TCR-Vβ rep er toire in pe riph eral T-cells,
sug ges tive of superantigen trig ger ing of T-cells
(235). Also, the clus ter ing of autoantibodies has
been ob served on the sur face of apoptotic cells in
sys temic vasculitis. Morever, it has been found that
ANCA in ter act with clus tered granule constituents
on the surface of apoptotic neutrophils (236,237).
The bind ing of ANCA to primed neu tro phils and
monocytes in duces re lease of cytokines (IL-8,
MCP-1) and pos si bly other fac tors that are strong
chemoattractants for more in flam ma tory cells.
ANCA also in duce a re spi ra tory burst with re lease
of re ac tive ox y gen spe cies (ROS) and degranu -
lation with re lease of lysosomal en zymes (HLE,
PR3, MPO), which leads to en do the lial cell in jury
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Fig ure 2. Sche matic pre sen ta tion of an intergrative view of the im mune mech a nisms in volved in the pathogenesis of
ANCA-as so ci ated vasculitis. Cytokines re leased due to in fec tion or other tis sue in jury cause prim ing of neu tro phils
and/or monocytes (A) and upregulation of ad he sion mol e cules (ELAM-1, ICAM-1, VCAM-1) on the en do the lium. Cir cu -
lat ing primed neu tro phils and/or monocytes ex press ANCA an ti gens (PR3, MPO), ad he sion mol e cules (LFA-1, VLA-4)
and FcγR on the cell sur face (B). Bind ing of ANCA to primed neu tro phils and monocytes in duces re lease of cytokines
such as IL-8, IL-1β, MCP-1 and pos si bly oth ers fac tors that are strong chemoattractants for more in flam ma tory cells pos -
si bly lead ing to granuloma for ma tion (C). Ad her ence of primed neu tro phils and/or monocytes to the en do the lium fol lowed 
by ac ti va tion of these cells by ANCA. Ac ti vated neu tro phils and monocytes re lease re ac tive ox y gen spe cies (ROS),
which leads to en do the lial cell in jury and even tu ally to necrotising in flam ma tion (D). PR3 and MPO from ANCA-ac ti vated
neu tro phils and/or monocytes re sults in en do the lial cell ac ti va tion, en do the lial cell in jury, or even en do the lial cell
apoptosis (E). PR3 and MPO serve as planted an ti gens re sult ing in in situ im mune com plexes, which in turn at tract other
neu tro phils (F). The mech a nism by which ANCA pro duc tion is trig gered and per pet u ated  re main un clear. How ever,
T-cells are though to play a sig nif i cant role in me di at ing the pro duc tion of ANCA by plasma cells, which are de rived from
an ti gen-spe cific B-cells (G). Adapted from ref. 163.    
(apoptosis) and even tu ally to necrotizing in flam ma -
tion. Ex cept for cytokines, ANCA stim u la tion also
ac ti vates en do the lial cells re sult ing in in creased ad -
her ence of primed and ac ti vated neu tro phils to their 
sur face. Con se quently, the re lease of cytotoxic
neutrophil con stit u ents can di rectly cause en do the -
lial cell dam age by di rect cytotoxicity, apoptosis and 
com ple ment ac ti va tion by immune complex bound
on the endothelial cell surface.
This con cep tual scheme is con sis tent with clin i -
cal ob ser va tions and an i mal model data, which
clearly in di cate that ANCA alone do not nec es sar ily
lead to dis ease man i fes ta tions. Co factors that lead
to ac ti va tion of in flam ma tory and en do the lial cells
seem to be re quired to ac ti vate var i ous patho genic
mech a nisms leading to small vessel vasculitis.
CON CLU SION
The sig nif i cance of ANCA as di ag nos tic mark ers 
for sys temic necrotizing vasculitis or id io pathic
necrotizing cres cen tic glomerulonephritis is well es -
tab lished. De tec tion of PR3-ANCA strongly sug -
gests a di ag no sis of Wegener′s granulomatosis,
and changes in se rum lev els of these autoantibo -
dies seem to mir ror dis ease ac tiv ity. MPO-ANCA
are as so ci ated with var i ous forms of sys temic nec -
ro tizing vasculitis in clud ing id io pathic necrotizing
cres cen tic glomerulonephritis. The di ag nos tic sig -
nif i cance of ANCA against other tar get an ti gens is
not clear. Their use ful ness in mea sur ing dis ease
ac tiv ity is at pres ent not clear, al though some stud -
ies suggest that rises in anti-MPO levels precede
relapses.
Many ques tions re main con cern ing the patho -
physi o logic role of ANCA, al though both in vi tro and
in vivo ex per i men tal data strongly sup port a patho -
genic role for ANCA in vasculitis and glomerulo -
nephritis. How ever, ANCA alone are not suf fi cient
and other, prob a bly ex og e nous fac tors seem nec -
es sary for dis ease ac ti va tion and (re)ac ti va tion. Cir -
cum stan tial ev i dence from hu man (Staph y lo coc cus 
aureus car riage) and ex per i men tal (e.g., the mer cu -
ric chlo ride model) stud ies sug gest that ex og e nous
fac tors, pos si bly of a microbial nature, are involved
in disease expression.
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Abbrevations
AECA antiendothelial cell an ti body
ACPA anticytoplasmic an ti body
a1-AT a1-antitrypsin
AIH au to im mune hep a ti tis
ANA antinuclear an ti body
ANCA antineutrophil cy to plas mic an ti body
a/P-ANCA ‘atyp i cal’ perinuclear ANCA
C-ANCA cy to plas mic ANCA
P-ANCA perinuclear ANCA
BPI bac te ri cidal/per me abil ity-in creas ing pro tein
CD Crohn’s dis ease
CG cathepsin G
CTD con nec tive tis sue dis eases
CSS Churg-Strauss syn drome
ELAM en do the lial ad he sion mol e cule
ELISA en zyme-linked immunosorbent as say
FcgR Fc-gamma re cep tors
GBM glo mer u lar base ment mem brane
GS-ANA granulocyte-spe cific ANA
HLE hu man leu ko cyte elastase
HMG1 and 2 high mo til ity group of nonhistone chro mo -
somal pro teins 1 and 2
H2O2 hy dro gen per ox ide
IB immunoblot
IBD in flam ma tory bowel dis ease
ICAM-1 intercellular ad he sion mol e cule-1
IIF in di rect immunofluorescence
IFN-γ in ter feron-γ
IL-1b interleukin-1b
IL-8 interleukin-8




LFA-1 lym pho cyte func tion an ti gen-1
LPS lipopolysaccharide
LZ lysozyme
MCP-1 monocyte chemoattractant pro tein-1
MPA mi cro scopic polyangiitis
MPO myeloperoxidase
MPO-ANCA myeloperoxidase - antineutrophic
 cytoplasma an ti body
PAN polyarteritis nodosa
PBC pri mary biliary cir rho sis
PM/DM polymyositis/dermatomyositis
PR3 proteinase-3
PR3-ANCA proteinase-3 antineutrophic cytoplasma
 an ti body
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PSC pri mary sclerosing cholangitis
RA rheu ma toid ar thri tis
RIA radioimmunoassay
ROS re ac tive ox y gen spe cies
SLE sys temic lupus erythematosus
SS Sjögren’s syn drome
SSc sys temic scle ro sis
TCR-Vβ -cell re cep tor
TNF-α tu mor ne cro sis fac tor a
UC ul cer ative co li tis
VCAM-1 vas cu lar ad he sion mol e cule-1
VLA-4 very late an ti gen-4
WG Wegener’s granulomatosis
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